Media stories about Fresenius Medical Care AG & Co. (NYSE:FMS) have been trending somewhat positive recently, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fresenius Medical Care AG & Co. earned a news sentiment score of 0.23 on Alpha One’s scale. Alpha One also assigned media stories about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the near future.
Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 0.21% during midday trading on Thursday, hitting $42.84. The stock had a trading volume of 79,970 shares. Fresenius Medical Care AG & Co. has a 12 month low of $38.05 and a 12 month high of $47.52. The stock’s 50-day moving average is $42.01 and its 200-day moving average is $41.16. The stock has a market cap of $26.24 billion, a PE ratio of 21.10 and a beta of 0.53.
Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings results on Wednesday, February 22nd. The company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The business earned $4.69 billion during the quarter, compared to analysts’ expectations of $4.74 billion. Fresenius Medical Care AG & Co. had a return on equity of 10.56% and a net margin of 6.67%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.04 earnings per share. Equities analysts anticipate that Fresenius Medical Care AG & Co. will post $2.55 EPS for the current year.
A number of equities research analysts recently commented on the company. Sanford C. Bernstein reissued a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Sunday, March 12th. DZ Bank AG reissued a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, March 7th. Zacks Investment Research lowered Fresenius Medical Care AG & Co. from a “buy” rating to a “hold” rating in a research report on Friday, February 24th. Finally, Societe Generale lowered Fresenius Medical Care AG & Co. from a “buy” rating to a “hold” rating in a research report on Friday, February 24th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $46.00.
Fresenius Medical Care AG & Co. Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065316/fresenius-medical-care-ag-co-fms-given-news-impact-rating-of-0-23.html
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.